1. GPCR/G Protein
    Neuronal Signaling
    Immunology/Inflammation
    Anti-infection
  2. Histamine Receptor
    SARS-CoV
  3. Azelastine

Azelastine 

Cat. No.: HY-B0462A
Handling Instructions

Azelastine, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.

For research use only. We do not sell to patients.

Azelastine Chemical Structure

Azelastine Chemical Structure

CAS No. : 58581-89-8

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other In-stock Forms of Azelastine:

Other Forms of Azelastine:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Azelastine, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2[1][2][3][4].

IC50 & Target[1]

H1 Receptor

 

In Vitro

Azelastine can significantly inhibit HNEpC proliferation, and therefore, be helpful in against airway remodeling[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[5]

Cell Line: Human nasal epithelial cells (HNEpC)
Concentration: 100 μM, 400 μM
Incubation Time: 21 days
Result: Inhibited HNEpC growth.

Western Blot Analysis[5]

Cell Line: Human nasal epithelial cells (HNEpC)
Concentration: 100 μM
Incubation Time: 7 days
Result: Significantly up-regulated the H1R, M1R and M3R levels.
In Vivo

Azelastine (4 mg/kg; p.o.; daily; for 8 weeks) significantly reduces blood glucose, HbA1c and serum alkaline phosphatase (ALP), osteocalcin and downregulates apolipoprotein B in diabetic hyperlipidemic rats model[2].
Azelastine (4 mg/kg; p.o.; daily; for 8 weeks) improves the lipid profile (LDL-c decrease and HDL-c increase) in diabetic hyperlipidemic rats model[2].
Azelastine (4 mg/kg; p.o.; daily; for 8 weeks) attenuates calcium deposition and aortic calcification in diabetic hyperlipidemic rats model[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male albino Wistar rats (150-170 g), diabetic hyperlipidemic rats model[2]
Dosage: 4 mg/kg
Administration: Oral administration, daily, for 8 weeks
Result: Ameliorated aortic calcification and increased apolipoprotein A expression along with a decline in apolipoprotein B.
Clinical Trial
Molecular Weight

381.90

Formula

C22H24ClN3O

CAS No.
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Azelastine
Cat. No.:
HY-B0462A
Quantity:
MCE Japan Authorized Agent: